



(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
12.06.2002 Bulletin 2002/24

(51) Int Cl.7: C07D 453/02, A61K 31/395,
A61P 43/00, C07D 451/02,
C07D 487/08, C07D 451/04,
C07D 401/14, C07D 401/12
// (C07D487/08, 241:00,
209:00)

(21) Application number: 01310151.4

(22) Date of filing: 04.12.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 05.12.2000 US 251225 P

(71) Applicant: PFIZER INC.
New York, N.Y. 10017 (US)


(72) Inventors:
• Katsu, Yasuhiro,
Pfizer Global Research & Developpt
Chita-gun, Aichi-ken 470-2393 (JP)

- Kawai, Makoto,
Pfizer Global Research & Developpt.
Chita-gun, Aichi-ken 470-2393 (JP)
- Kolke, Hiroki,
Pfizer Global Research & Developpt.
Chita-gun, Aichi-ken 470-2393 (JP)
- Nukul, Seiji, Pfizer Global Research & Developpt.
Chita-gun, Aichi-ken 470-2393 (JP)

(74) Representative: Wood, David John et al
PFIZER LIMITED,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) N-benzenesulfonyl L-proline compounds as bradykinin antagonists

(57) This invention provides a compound of the formula (I):



substituted with C₅-11 azabicycloalkyl;
(b) -C₃-9 azacycloalkyl-NH-(C₅-11 azabicycloalkyl optionally substituted with C₁-4 alkyl);
(c) -NH-C₁-3 alkyl-C(O)-C₅-11 diazabicycloalkyl;
(d) -NH-C₁-3 alkyl-C(O)-NH-C₅-11 azabicycloalkyl, the C₅-11 azabicycloalkyl being optionally substituted with C₁-4 alkyl;
(e) -C₃-9 azacycloalkyl optionally substituted with C₃-9 azacycloalkyl; or
(f) -NH-C₁-5 alkyl-NH-C(O)-C₄-9 cycloalkyl-NH₂.

These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc. This invention also provides a pharmaceutical composition comprising the above compound.

or the pharmaceutically acceptable salts thereof where-
in X¹ and X² are halo; R¹ and

R² are independently hydrogen or C₁-4 alkyl; R³ and
R⁴ are each hydrogen or halo; and
R⁵ is

(a) -C₃-9 diazacycloalkyl optionally

Description**Technical Field**

5 [0001] This invention relates to novel N-benzenesulfonyl L-proline compounds. These compounds are useful as antagonists of bradykinin, and are thus useful in the treatment of inflammation, asthma, allergic rhinitis, pain or the like in mammalian, especially humans. The present invention also relates to a pharmaceutical composition comprising the above compounds.

Background Art

10 [0002] Bradykinin ("BK") is generated under normal conditions in mammalia by the action of various plasma enzymes such as kallikrein on high molecular weight kininogens. It is widely distributed in mammals, and relates its two receptor subtypes, B_1 and B_2 . The actions of BK at the B_2 receptor include mainly contraction of arterial and venous preparations, 15 although it can cause relaxation of peripheral resistance vessels as well.

15 [0003] Many of the more important functions of BK, such as increases in vascular permeability, pain, and vasodilation, however, are mediated by the B_2 receptor. These effects at the B_2 receptor are believed to be responsible for BK's role in numerous diseases, such as inflammation, cardiovascular disease, pain, and the common cold. Hence antagonists at the B_2 receptor should find considerable therapeutic applications. Most of the efforts in this area thus 20 far have been directed at peptidic analogues of the BK structure, some of which have been studied as analgesics and antiinflammatory agents.


25 [0004] Numerous N-benzenesulfonyl L-proline compounds as a B_2 antagonist have been synthesized, and disclosed in a number of patent publications such as international publication Nos. WO 97/41104, WO 96/13485, WO 99/00387, WO 98/24783, WO 98/03503, WO 97/24349, WO 97/07115 and WO 96/40639.

30 [0005] International Publication Number WO 98/24783, WO 98/03503, WO 97/24349, WO 97/07115 disclose a variety of N-benzenesulfonyl L-proline compounds as antagonists of bradykinin.

35 [0006] It would be desirable if there were provided a non-peptide antagonist of the B_2 receptor, having an improved B_2 antagonistic activity and a good metabolic stability against human liver microsomes.

Brief Disclosure of the Invention

40 [0007] The present invention provides a compound of the following formula:



55 or the pharmaceutically acceptable salts thereof wherein

X^1 and X^2 are independently halo or C_{1-4} alkyl;

R^1 and R^2 are independently hydrogen or C_{1-4} alkyl;

R^3 and R^4 are independently hydrogen or halo; and

R^5 is

- 5 (a) $-C_{3-9}$ diazacycloalkyl optionally substituted with C_{5-11} azabicycloalkyl;
- (b) $-C_{3-9}$ azacycloalkyl-NH-(C_{5-11} azabicycloalkyl optionally substituted with C_{1-4} alkyl);
- (c) $-NH-C_{1-3}$ alkyl-C(O)- C_{5-11} diazabicycloalkyl;
- (d) $-NH-C_{1-3}$ alkyl-C(O)-NH- C_{5-11} azabicycloalkyl, the C_{5-11} azabicycloalkyl being optionally substituted with C_{1-4} alkyl;
- (e) $-C_{3-9}$ azacycloalkyl optionally substituted with C_{3-9} azacycloalkyl; or
- (f) $-NH-C_{1-5}$ alkyl-NH-C(O)- C_{4-9} cycloalkyl-NH₂.

10 [0008] The N-benzenesulfonyl L-proline compounds of this invention have an antagonistic action towards bradykinin and are thus useful in therapeutics, particularly for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, pancreatitis, neovascularization, corneal haze, glaucoma, ocular pain, ocular hypertension or the like in mammalian, especially humans.

15 [0009] The N-benzenesulfonyl L-proline compounds of this invention have an antagonistic action towards bradykinin and are thus useful in therapeutics, particularly for the treatment of Amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, multiple sclerosis, stroke, head trauma, post-surgical brain edema, brain edema (general), cytotoxic brain edema (such as that associated with brain tumors, stroke, head trauma, etc.), brain edema associated with metabolic diseases (renal failure, pediatric metabolic diseases, etc.), rheumatoid arthritis, osteoarthritis, migraine, neuropathic pain, pruritis, brain tumor, pseudotumor cerebri, glaucoma, hydrocephalus, spinal cord trauma, spinal cord edema, neurodegenerative diseases, respiratory diseases, diuresis, natriuresis calciuresis, COPD (chronic obstructive pulmonary disease), post-traumatic brain injury, itching, sepsis or the like in mammalian, especially humans.

20 [0010] The present invention provides a pharmaceutical composition for the treatment of disease conditions mediated by bradykinin, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I).

25 [0011] Further, the present invention also provides a pharmaceutical composition for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, pancreatitis, neovascularization, corneal haze, glaucoma, ocular pain, ocular hypertension or the like, which comprises a therapeutically effective amount of the N-benzenesulfonyl L-proline compound of formula (I) or its pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier.

30 [0012] Further, the present invention also provides a pharmaceutical composition for the treatment of Amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, Multiple sclerosis, Stroke, head trauma, Post-surgical brain edema, Brain edema (general), Cytotoxic brain edema (such as that associated with brain tumors, stroke, head trauma, etc.), Brain edema associated with metabolic diseases (renal failure, pediatric metabolic diseases, etc.), Rheumatoid arthritis, Osteoarthritis, Migraine, Neuropathic Pain, Pruritis, Brain Tumor, Pseudotumor cerebri, Glaucoma, Hydrocephalus, Spinal cord trauma, Spinal cord edema, neurodegenerative diseases, respiratory diseases, diuresis, natriuresis calciuresis, COPD (chronic obstructive pulmonary disease), post-traumatic brain injury, itching or Sepsis, which comprises a therapeutically effective amount of a compound of formula (I) or its pharmaceutically acceptable carrier.

35 [0013] Also, the present invention provides a method for the treatment of disease conditions mediated by bradykinin, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I).

40 [0014] Further, the present invention provides a method for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, pancreatitis, neovascularization, corneal haze, glaucoma, ocular pain, ocular hypertension or the like, in a mammalian subject, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I).

Detailed Description of the Invention

45 [0015] As used herein, the term "halo" is fluoro, chloro, bromo or iodo (preferably fluoro or chloro).

50 [0016] As used herein, the term "alkyl" means straight or branched chain saturated radicals, including, but not limited to methyl, ethyl, *n*-propyl, *isopropyl*, *n*-butyl, *isobutyl*, *secondary-butyl*, *tertiary-butyl*.

55 [0017] As used herein, the term " C_{4-9} cycloalkyl" means monocyclic alkyl having 4 to 9 carbon atoms, such as cyclobutyl, cyclopentyl, cycloheptyl, cyclohexyl, and the like.

[0018] As used herein, the term "**C₃₋₉ azacycloalkyl, C₃₋₉ diazacycloalkyl, C₅₋₁₁ azabicycloalkyl or C₅₋₁₁ diazabicycloalkyl**" means a group wherein one or two carbons of mono- or bicyclic alkyl ring components are substituted by nitrogen atoms, included, but not limited to, azetidinyl, piperazinyl, piperidino, piperidinyl, pyrrolidinyl, azabicyclo[3.3.0]octyl, quinuclidinyl, azabicyclo[3.2.1]octyl, azabicyclo[3.3.1]nonyl, azabicyclo[2.2.2]octyl or diazabicyclo[3.2.1]octyl.

[0019] In the formula (I), **R⁵** is preferably (a) -C₃₋₉ diazacycloalkyl optionally substituted with C₅₋₁₁ azabicycloalkyl or (c) -NH-C₁₋₃ alkyl-C(O)-C₅₋₁₁ diazabicycloalkyl, more preferably (a) -C₄₋₈ diazacycloalkyl optionally substituted with C₆₋₁₀ azabicycloalkyl or -NH-C₁₋₃ alkyl-C(O)-C₆₋₁₀ diazabicycloalkyl, further preferably azabicyclo[2.2.2]octyl-piperazinyl, diazabicyclo[3.2.1]octyloxomethylamino or diazabicyclo[3.2.1]octyl-oxoethylamino, and most preferably azabicyclo[2.2.2]octyl-piperazinyl or diazabicyclo[3.2.1]octyl-oxomethylamino.

[0020] Preferred compounds of this invention are those of the formula (I) wherein

X¹ and X² are chloro;

R¹ and R² are independently hydrogen, methyl or ethyl;

R³ and R⁴ are independently hydrogen or fluoro; and

R⁵ is

(a) -C₄₋₈ diazacycloalkyl optionally substituted with C₆₋₁₀ azabicycloalkyl;

(b) -C₃₋₆ azacycloalkyl-NH-(C₆₋₁₀ azabicycloalkyl optionally substituted with C₁₋₄ alkyl);

(c) -NH-C₁₋₃ alkyl-C(O)-C₆₋₁₀ diazabicycloalkyl;

(d) -NH-C₁₋₃ alkyl-C(O)-NH-C₆₋₁₀ azabicycloalkyl, the C₆₋₁₀ azabicycloalkyl being optionally substituted with C₁₋₄ alkyl;

(e) -C₄₋₈ azacycloalkyl optionally substituted with C₄₋₈ azacycloalkyl; or

(f) -NH-C₁₋₅ alkyl-NH-C(O)-C₅₋₈ cycloalkyl-NH₂.

[0021] Much preferred compounds of this invention are those of the formula (I) wherein

R¹ and R² are methyl; R³ and R⁴ are hydrogen; and

R⁵ is azabicyclo[2.2.2]octyl-piperazinyl, azabicyclo[3.2.1]octyloxymethylamino, diazabicyclo[3.2.1]octyl-oxomethylamino, diazabicyclo[3.2.1]octyloxomethylamino, methylazabicyclo[3.2.1]octyl-aminooxomethylamino, methylazabicyclo[3.2.1]octyl-aminooxomethylamino, ethylazabicyclo[3.2.1]octylaminooxomethylamino, piperidinyl-piperidinyl, [(aminocyclohexyl)carbonyl]amino or [(aminocyclohexyl)carbonyl]amino]butylamino.

[0022] Also, preferred compounds of this invention are those of the formula (I) wherein

R⁵ is azabicyclo[2.2.2]octyl-piperazinyl, azabicyclo[3.2.1]octyloxymethylamino, diazabicyclo[3.2.1]octyl-oxomethylamino, methylazabicyclo[3.2.1]octylaminooxomethylamino, piperidinyl-piperidinyl or [(aminocyclohexyl)carbonyl]amino]propylamino.

[0023] Preferred individual compounds of this invention are:

40 8-[[3-[(2S)-2-[[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]carbonyl]pyrrolidinyl]sulfonyl]-2,6-dichlorobenzyl]oxy]-2,4-dimethylquinoline; and

(2S)-N-[2-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-1-[[2,4-dichloro-3-[(2,4-dimethyl-8-quinoliny)oxy]methyl]phenyl]sulfonyl]-2-pyrrolidinecarboxamide, and a salt thereof.

45 General Synthesis

[0024] The N-benzenesulfonyl L-proline compounds of formula (I) of this invention may be prepared by a variety of synthetic methods.

Preparation Method A:

[0025]

5

$$\begin{array}{ccc}
 \text{R}^1 & & \text{R}^1 \\
 | & & | \\
 \text{N} & & \text{N} \\
 | & & | \\
 \text{R}^2 & & \text{R}^2 \\
 & & \\
 & & \text{O} \\
 & & | \\
 & & \text{X}^1 \\
 & & | \\
 & & \text{X}^2 \\
 & & | \\
 & & \text{S} \\
 & & | \\
 & & \text{O}_2 \\
 & & | \\
 & & \text{N} \\
 & & | \\
 & & \text{R}^3 \\
 & & | \\
 & & \text{R}^4 \\
 & & \\
 & & \text{O} \\
 & & | \\
 & & \text{C} \\
 & & | \\
 & & \text{O} \\
 & & | \\
 & & \text{H} \\
 & & \\
 & & \text{(II)} \\
 & & \\
 & & \text{amine (HR}^5\text{)} / \text{WSC} / \text{HOEt} \\
 & & \text{CH}_2\text{Cl}_2 \\
 & & \\
 & & \text{R}^1 \\
 & & | \\
 & & \text{N} \\
 & & | \\
 & & \text{R}^2 \\
 & & \\
 & & \text{O} \\
 & & | \\
 & & \text{X}^1 \\
 & & | \\
 & & \text{X}^2 \\
 & & | \\
 & & \text{S} \\
 & & | \\
 & & \text{O}_2 \\
 & & | \\
 & & \text{N} \\
 & & | \\
 & & \text{R}^3 \\
 & & | \\
 & & \text{R}^4 \\
 & & \\
 & & \text{O} \\
 & & | \\
 & & \text{C} \\
 & & | \\
 & & \text{O} \\
 & & | \\
 & & \text{R}^5 \\
 & & \\
 & & \text{(I)}
 \end{array}$$

(wherein X1, X2, R1, R2, R3, R4 and R5 are as already defined; and WSC is 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride. HOEt is 1-hydroxybenzotriazole hydrate.

25 Scheme A-1

[0026] To a stirred solution of the acid of formula (II) (150 mg, 0.294 mmol) and amine H-R⁵ (0.441 mmol) in CH_2Cl_2 (15 mL) were added HOBt (67 mg, 0.441 mmol) and WSC (84 mg, 0.441 mmol) at room temperature and the mixture was stirred overnight. To the mixture was added H_2O (5 mL) and the organic layer was separated, washed with saturated aqueous NaHCO_3 , brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. Column chromatography (NH gel, 200-350 mesh, 8 g, $\text{CH}_2\text{Cl}_2/\text{MeOH} = 99/1$ to 90/10) afforded the coupling product including a compound of formula (I).

[0027] In the described method A, 1,3-diisopropylcarbodiimide in place of WSC, t-BuOH-CH₂Cl₂(1-1), DMF, or AcOEt in place of CH₂Cl₂ were also used. For purification process, appropriate regins or solid-phase extraction method was also utilized when the small amount of the starting material (II) (about 50 μ mol) were used.

35 [0028] To a stirred solution of the coupling product including a compound of formula (I) (0.0964 mmol) in MeOH was added HCl-MeOH (2.9 mL) and the mixture was stirred for 15 minutes. Then the solvent was removed *in vacuo* to provide the HCl salt.

[0029] Alternately, the N-benzenesulfonyl L-proline compounds of formula (Ia-II) were prepared by reaction of a compound (III) with a compound of formula (IV) as indicated in the following Scheme A-II.

40

45

50

Chemical reaction scheme showing the condensation of compound (III) with compound (IV) to form compounds (Ia-II). Compound (III) is a 2,3-dihydro-1H-1,4-dihydroquinolin-2-one derivative with substituents X^1 , X^2 , X^3 , R^3 , R^4 , and R^{5A} . Compound (IV) is a 2-hydroxy-1,4-dihydroquinolin-2-one derivative with substituents R^1 and R^2 . The reaction results in the formation of compounds (Ia-II), which are 2,3-dihydro-1H-1,4-dihydroquinolin-2-one derivatives with a fused ring system containing X^1 , X^2 , X^3 , R^1 , R^2 , R^3 , R^4 , and R^{5A} .

(wherein R^{5A} is hydroxy, C_{1-4} alkoxy (such as methoxy and ethoxy) or R^5 ; X^3 is halo; and the other symbols are as already defined or as already defined).


Scheme A-II

[0030] This method utilizes a synthesis as described in WO97/07115. This reaction is carried out in a suitable reaction-inert solvent (anhydrous). Suitable solvents include, for example, aromatic hydrocarbons such as benzene, toluene and xylene; alcohols such as methanol, ethanol, propanol and butanol; ethers such as diethyl ether, dioxane and tetrahydrofuran; halogenated hydrocarbons such as methylene dichloride, chloroform, dichloromethane and dichloroethane; amides such as N,N-dimethylformamide; and nitriles such as acetonitrile. This reaction is carried out at a temperature between -10 °C and 100 °C, preferably from 0 °C to 50 °C for 5 minutes to 24 hours, preferably 30 minutes to 5 hours.

10 [0031] In addition, the compounds (III) and (IV) which can be used herein may be either already known or may be prepared according to the reported methods.

Preparation Method B:

15 [0032] The compounds of formula (III) was prepared by the reaction of a compound (V) with a compound of formula (VI) as indicated in the following **Scheme B**.



(wherein X^3 is halo; and the other symbols are as already defined)

30 Scheme B

[0033] This method utilizes a synthesis as described in WO97/07115. This reaction is carried out in the presence of base in a suitable reaction-inert solvent. Suitable base includes, for example, triethylamine. Suitable solvents include, for example, aromatic hydrocarbons such as benzene, toluene and xylene; alcohols such as methanol, ethanol, propanol and butanol; ethers such as diethyl ether, dioxane and tetrahydrofuran; halogenated hydrocarbons such as chloroform, dichloromethane and dichloroethane; amides such as N,N-dimethylformamide; and nitriles such as acetonitrile. This reaction is carried out at a temperature between -10 °C and 100 °C, preferably from 0 °C to 40 °C for 5 minutes to 24 hours, preferably 30 minutes to 3 hours.

[0034] The compounds of formula (I), and the intermediates above-mentioned preparation methods can be isolated and purified by conventional procedures such as recrystallization or chromatographic purification.

[0035] The optically active compounds of this invention can be prepared by several methods known to a skilled person in the art. For example, the optically active compounds of this invention may be obtained by chromatographic separation or fractional crystallization from the final compounds or the intermediates in racemic form thereof. Alternatively, the optically active compounds may be prepared by optically selective reaction, enzymatic hydrolysis or reactions using optically active intermediates.

[0036] The N-benzenesulfonyl L-proline compounds of this invention possess an asymmetric center. Hence, the compounds can exist in separated (+)- and (-)-optically active forms, as well as in racemic one thereof. The present invention includes all such forms within its scope. Individual isomers can be obtained by known methods, such as optically selective reaction or chromatographic separation in the preparation of the final product or its intermediate.

50 [0037] The present invention includes salt forms of the compounds (I) as obtained above.

[0038] Insofar as the N-benzenesulfonyl L-proline compounds of this invention are basic compounds, they are capable of forming a wide variety of different salts with various inorganic and organic acids.

[0039] The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned N-benzenesulfonyl L-proline base compounds of this invention of formula (I) are those which form non-toxic acid addition salts, i.e., salts containing pharmaceutically acceptable anions, such as the chloride, bromide, iodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bi-tartrate, succinate, malate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)). The acid addition salts can be prepared

by conventional procedures.

[0040] The N-benzenesulfonyl L-proline compounds of the present invention of formula (I) exhibit significant bradykinin receptor-binding activity and therefore, are of value in the treatment of a wide variety of clinical conditions in mammals, especially human. Such conditions include inflammation, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma and the like.

[0041] Therefore, these compounds are readily adapted to therapeutic use as bradykinin antagonists for the control and/or treatment of any of the aforesaid clinical conditions in mammals, including humans.

[0042] Also, the compounds of formula (I) may be expected more effective therapeutic effects with being co-administered with H₁-antagonist.

[0043] Further, the present invention also encompasses a pharmaceutical composition for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, cystitis, pancreatitis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, multiple sclerosis, stroke, head trauma, post-surgical brain edema, brain edema (general), cytotoxic brain edema (such as that associated with brain tumors, stroke, head trauma, etc.), brain edema associated with metabolic diseases (renal failure, pediatric metabolic diseases, etc.), rheumatoid arthritis, osteoarthritis, migraine, neuropathic pain, pruritis, brain tumor, pseudotumor cerebri, glaucoma, hydrocephalus, spinal cord trauma, spinal cord edema, neurodegenerative diseases, respiratory diseases, diuresis, natriuresis calciuresis, COPD (chronic obstructive pulmonary disease), post-traumatic brain injury, itching, sepsis, or the like, which comprises a therapeutically effective amount of the N-benzenesulfonyl L-proline compound of formula (I) and H₁-antagonist or their pharmaceutically acceptable salt together with a pharmaceutically acceptable carrier.

[0044] The compounds of the invention may advantageously be employed in combination with one or more other therapeutic ingredients selected from an antibiotic, anti-fungal, or anti-viral agent, an anti-histamine, a non-steroidal antiinflammatory drug or disease modifying anti-rheumatic drug.

[0045] The combination with an anti-histamine (H₁ antagonist) is particularly favored for use in the prophylaxis and treatment of asthma and rhinitis. Examples of anti-histamine are chlorpheniramine, brompheniramine, clemastine, ketotifen, azatadine, loratadine, terfenadine, cetirizine, astemizole, tazifylline, levocabastine, diphenhydramine, temelastine, etolotifen, acrivastine, azelastine, ebastine, mequitazine, KA-398, FK-613, mizolastine, MDL-103896, levocetirizine, mometasone furoate, DF-1111301, KC-11404, carebastine, ramatroban, desloratadine, noberastine, selenotifen, alinastine, E-4716, eflterizine, tritoqualine, norasternizole, ZCR-2060, WY-49051, KAA-276, VUF-K-9015, tagorizine, KC-11425, epinastine, MDL-28163 terfenadine, HSR-609, acrivastine and BMY-25368.

Method for assessing biological activities:

[0046] The activity of the N-benzenesulfonyl L-proline compounds of the present invention, as bradykinin antagonists, is determined by their ability to inhibit the binding of bradykinin at its receptor sites in recombinant human bradykinin B₂ receptor expressing CHO-K1 cells (from Receptor Biology, Inc.) employing radioactive ligands.

[0047] The bradykinin antagonist activity of the N-benzenesulfonyl L-proline compounds is evaluated by using the standard assay procedure described in, for example, Baenziger N. L., Jong Y.-J. I., Yocom S. A., Dalemar L. R., Wilhelm B., Vaurek R., Stewart J. M., *Eur. J. Cell Biol.*, 1992, 58, 71-80. This method essentially involves determining the concentration of the individual compound required to reduce the amount of radiolabelled bradykinin ligands by 50% at their receptor sites in CHO-K1 cells, thereby affording characteristic IC₅₀ values for each compound tested.

[0048] More specifically, the assay is carried out as follows. First, rat, guinea pig or monkey ileum tissues are minced and suspended in 25mM piperazine-N,N'-bis (2-ethanesulfonic acid (PIPES) buffer (pH 6.8) containing 0.1 mg/ml of soybean trypsin inhibitor. Then, the tissues are homogenized using a Polytron homogenizer at setting 7 for 30 seconds three times, and then rehomogenized with a Teflon-coated homogenizer. The homogenized suspension was centrifuged at 1,200 X g for 15 minutes. The pellet was rehomogenized and then centrifuged at 1,200 X g for 15 minutes. These supernatant were centrifuged at 10,000 X g for 60 minutes. The tissue pellets, CHO-K1 cell membrane are suspended in 25 mM PIPES buffer (pH6.8) containing 1.25 mM dithiothreitol, 1.75 µg/ml bacitracin, 1 mM *o*-phenanthroline, 18.75 µM captopril, 1.25 mg/ml bovine serum albumin (BSA), to prepare tissue/cell suspensions. Then, 10 µl of test compound solution dissolved in phosphate buffered saline (PBS, pH 7.5) containing 2% DMSO (final) and 0.1% BSA (w/v) or 10ml of 12.5 mM bradykinin in PBS (pH 7.5) containing 0.1% BSA (w/v) are placed in a reaction 96-well plate. 15 µl of 8.3 nM [³H]bradykinin is added to the compound solution or bradykinin solution in the 96-well plate. Finally 100 µl of the tissue or cell suspension are added to the mixture in the plate, and incubated at room temperature for 1 hour under the dark. After incubation, the resultant product in the reaction plates is filtered through 0.1% polyethylenimine presoaked LKB filtermat. The filtrate is washed using a Skatron auto cell harvester. The tissue bound radioactivity is determined using a LKB betaplate counter. The IC₅₀ value is determined using the equation:

$$\text{Bound} = B_{\max} / (1 + [I]/IC_{50})$$

wherein [I] means the concentration of the test compound.

[0049] All compounds prepared in the working examples as described below were tested by this method, and showed an IC_{50} value of 0.1 nM to 4 nM in CHO-K1 cells with respect to inhibition of binding at its receptor.

[0050] The most preferred compounds prepared in the working examples as described below were tested by this method, and showed an IC_{50} value of 0.5 nM to 3.3 nM in CHO-K1 cells with respect to inhibition of binding at its receptor.

[0051] The possibility of drug-drug interaction of the N-benzenesulfonyl, L-proline compounds of the present invention, as bradykinin antagonists, is determined by their ability to inhibit the testosterone 6β -hydroxylase activity raised by CYP3A4 which is most abundant subtype of cytochrome P-450 in human.

CYP3A4 interaction assay:

[0052] This method essentially involves determining the concentration of the individual compound required to reduce the amount of 6β -hydroxytestosterone by 50%.

[0053] More specifically, the assay is carried out as follows. Human liver microsomes (0.2 mg/ml) were mixed with appropriate concentrations of kinin B₂ antagonist. Then, incubated with the presence of 50 μ M testosterone, 1.3 mM NADP⁺, 0.9 mM NADH, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl₂, and glucose-6-phosphate dehydrogenase (8 units/ml) in a total volume of 0.2 ml of 100 mM potassium phosphate buffer, pH 7.4, at 37 °C. After incubation (20 minutes), 10 μ l of methylalchol containing internal standard was withdrawn. The medium was filtrated by membrane filter with centrifugation at 1,800 x g for 10 minutes, and the resulting filtrate was taken.

[0054] A 6β -hydroxylated metabolite of testosterone in samples was analyzed by HPLC. A sample of 20 μ l was injected to the HPLC system equipped with a Polymer C18 column (2.0 x 75 mm). The mobile phase consisted of 24% to 66% acetonitrile linear gradient including 10 mM ammonium phosphate, and with a flow rate of 0.35 ml/min.

[0055] The IC_{50} value is determined using the equation:

$$\text{Activity} = \text{Activity}_{\text{control}} / (1 + [I]/IC_{50})$$

wherein [I] means the concentration of the test compound.

[0056] The most preferred compounds as mentioned above of Working Examples showed IC_{50} values of more than 10 μ M.

Human liver microsome assay:

[0057] $T_{1/2}$ value against human liver microsome was calculated by conventional procedure. More specifically, human liver microsomes (0.2 mg/ml) were mixed with 1 μ M of kinin B₂ antagonist and incubated with in the presence of 1.3 mM NADP⁺, 0.9 mM NADH, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl₂, and glucose-6-phosphate dehydrogenase (8 units/ml) in a total volume of 1.2 ml of 100 mM potassium phosphate buffer, pH 7.4, at 37 °C. At specified incubation times (0, 5, 10, 30 minutes), an aliquot of 100 μ l was withdrawn from the reaction mixture and mixed with 1 ml of acetonitrile containing internal standard. Protein was precipitated by centrifugation at 1,800 x g for 10 minutes, and the resulting supernatant was taken.

[0058] Kinin B₂ antagonist in samples were analyzed by LS/MS/MS, in a Sciex API-300 mass spectrometer linked with a Hawlett-Pakkard HP1100 HPLC system. A sample of 20 μ l was injected to the HPLC system equipped with a Wakosil II 5C18 HG column (2.0 x 150 mm). The mobile phase consisted of 80% acetonitrile including 10 mM ammonium acetate, and the elution was isocratic with a flow rate of 0.3 ml/min. Part of the eluent from the HPLC column was introduced into the atmospheric ionization source via an ion spray interface. $T_{1/2}$ value is determined using the equation:

$$T_{1/2} = 0.693/k$$

wherein k is elimination rate constant of the test compound.

[0059] The compounds of the formula (I) exhibit excellent biological activity *in vitro* and *in vivo* as bradykinin antagonists. Additionally, the compound of the formula (I) was stable against metabolism in human liver microsomes assay experiments. The most preferred compounds of Working Examples showed $T_{1/2}$ values of more than 10 minutes.

[0060] The compound of this invention showed a good IC_{50} in CHO-K1 cells and a good $T_{1/2}$ value, which are essential

for a practical drug.

[0061] The N-benzenesulfonyl L-proline compounds of formula (I) of this invention can be administered via either the oral, parenteral or topical routes to mammals. In general, these compounds are most desirably administered to humans in doses ranging from 0.3 mg to 750 mg per day, preferably from 10 mg to 500 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated, the disease state being treated and the particular route of administration chosen. However, for example, a dosage level that is in the range of from 0.06 mg to 2 mg per kg of body weight per day is most desirably employed for treatment of inflammation.

[0062] The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the above routes previously indicated, and such administration can be carried out in single or multiple doses. More particularly, the novel therapeutic agents of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various nontoxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging 5% to 70% by weight, preferably 10% to 50% by weight.

[0063] For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dipotassium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

[0064] For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH>8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

Examples

[0065] The invention is illustrated in the following non-limiting examples in which, unless stated otherwise: all operations were carried out at room or ambient temperature, that is, in the range of 18-25 °C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure with a bath temperature of up to 60 °C; reactions were monitored by thin layer chromatography (tlc) and reaction times are given for illustration only; melting points (m.p.) given are uncorrected (polymorphism may result in different melting points); the structure and purity of all isolated compounds were assured by at least one of the following techniques: tlc (Merck silica gel 60 F₂₅₄ precoated TLC plates or Merck NH₂ F_{254s} precoated HPTLC plates), mass spectrometry, nuclear magnetic resonance (NMR), infrared red absorption spectra (IR) or microanalysis. Yields are given for illustrative purposes only. Flash column chromatography was carried out using Merck silica gel 60 (230-400 mesh ASTM) or Fuji SiliSia Chromatorex® DU3050 (Amino Type, 30~50 µm). Low-resolution mass spectral data (EI) were obtained on a Automass 120 (JEOL) mass spectrometer. Low-resolution mass spectral data (ESI) were obtained on a Quattro II (Micromass) or ZMD (Micromass) mass spectrometer. NMR data was determined at 270 MHz (JEOL JNM-LA 270 spectrometer) or 300 MHz (JEOL JNM-LA300) using deuterated chloroform (99.8% D) or dimethylsulfoxide (99.9% D) as solvent unless indicated otherwise, relative to tetramethylsilane (TMS) as internal standard in parts per million (ppm); conventional abbreviations used are: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. = broad, etc. IR spectra were measured by a Shimazu infrared spectrometer (IR-470). Optical rotations were measured using a JASCO DIP-370 Digital Polarimeter (Japan Spectroscopic CO, Ltd.).

Chemical symbols have their usual meanings; b.p. (boiling point), m.p. (melting point), 1 (liter(s)), ml (milliliter(s)), g (gram(s)), mg(milligram(s)), mol (moles), mmol (millimoles), eq. (equivalent(s)).

EXAMPLE 1

8-[(3-[(2S)-2-[(4-[(3S)-1-AZABICYCLO[2.2.2]OCT-3-YL]-1-PIPERAZINYLCARBONYL]PYRROLIDINYL]SULFONYL]2,6-DICHLOROBENZYL]OXY]-2,4-DIMETHYLQUINOLINE, HCl SALT

5

A. 1-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-4-berzyl-2,6-piperazinedione

[0066] To a solution of *N*-benzyliminodiacetic acid (2.23 g, 10.0 mmol) in THF (30 mL) was added 1,1'-carbonyl bis-1*H*-imidazole (3.57 g, 22.0 mmol) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at reflux temperature for 30 min (until the evolution of CO₂ gas ceased, giving a clear solution), then cooled to room temperature. To the resulting mixture was added a solution of (3*S*)-3-aminoquinuclidine dihydrochloride (2.00 g, 10.0 mmol) and triethylamine (3.06 mL, 22.0 mmol) in THF (10 mL) stirred at room temperature under nitrogen atmosphere for 30 min *via* a cannula. The combined reaction mixture was stirred under reflux for 24 h, then cooled to room temperature and quenched with H₂O (10 mL). The organic layer was extracted with EtOAc (50 x 2 mL) and the combined organic layers were dried over MgSO₄, concentrated *in vacuo*. The residue was purified by column chromatography (NH gel, 200-350 mesh, 150 g, EtOAc) to give a product (2.17 g, 69%) as a white solid.

¹H NMR (CDCl₃) δ: 7.39-7.27 (m, 5 H), 4.73-4.66 (m, 1 H), 3.77-3.69 (m, 1 H), 3.60 (s, 2 H), 3.38 (s, 4 H), 3.34-3.29 (m, 1 H), 3.02-2.93 (m, 1 H), 2.90-2.75 (m, 3 H), 1.91-1.61 (m, 4 H), 1.38-1.28 (m, 1 H)

B. (3*S*)-3-(4-Benzyl-1-piperazinyl)-1-azabicyclo[2.2.2]octane

[0067] To a solution of 1-[(3*S*)-1-azabicyclo[2.2.2]oct-3-yl]-4-benzyl-2,6-piperazinedione (1.90 g, 6.00 mmol) in 1,4-dioxane (40 mL) was added LiAlH₄ (911 mg, 24.0 mmol) at room temperature under nitrogen atmosphere. The resulting suspension was stirred under reflux for 3.5 h, then cooled to 0 °C. The mixture was diluted with Et₂O (80 mL), then treated carefully with Na₂SO₄·10 H₂O (9.1 g) and anhydrous KF (1 g). After the resulting white suspension was stirred vigorously at room temperature for 30 min, the white precipitate was removed by filtration through a pad of celite. The filtrate was concentrated *in vacuo* and the residue was purified by column chromatography (NH gel, 200-350 mesh, 40 g, EtOAc) to give a product (1.39 g, 81%) as a white solid.

¹H NMR (CDCl₃) δ: 7.32-7.24 (m, 5 H), 3.51 (s, 2 H), 3.01-1.98 (m, 16 H), 1.83-1.59 (m, 2 H), 1.48-1.40 (m, 1 H), 1.30-1.21 (m, 1 H)

C. (3*S*)-3-(1-Piperazinyl)-1-azabicyclo[2.2.2]octane

[0068] A mixture of (3*S*)-3-(4-benzyl-1-piperazinyl)-1-azabicyclo[2.2.2]octane (1.25 g, 4.37 mmol) and 400 mg of Pd (OH)₂ (20 wt% on carbon) in MeOH (60 mL) was stirred at room temperature under hydrogen atmosphere (4 atm) for 6 h. The reaction mixture was filtered through a pad of celite and the filtrate was concentrated *in vacuo* to give a product (850 mg, quant.).

¹H NMR (CDCl₃) δ: 3.01-2.00 (m, 16 H), 1.81-1.65 (m, 2 H), 1.50-1.36 (m, 1 H), 1.36-1.20 (m, 1 H)

D. 8-[(3-[(2S)-2-[(4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]carbonyl]pyrrolidinyl]sulfonyl]-2,6-dichlorobenzyl]oxy]-2,4-dimethylquinoline, HCl salt

[0069] This compound was prepared by a procedure similar to that described in method A and AcOEt was used for the extraction solvent. Column chromatography (NH gel, 200-350 mesh, AcOEt/MeOH = 10/1-5/1) afforded a product.

45 Free base

¹H-NMR (CD₃OD) δ: 8.09 (d, J=8.6 Hz, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.58 (dd, J=8.4, 1.0Hz, 1H), 7.44 (t, J=8.2 Hz, 1H), 7.27 (dd, J=8.4, 1.0Hz, 1H), 7.18 (d, J=1.0 Hz, 1H), 5.70-5.44 (m, 2H), 4.94 (dd, J=8.6, 3.6 Hz, 1H), 3.65-3.30 (m, 6H), 2.94-2.60 (m, 4H), 2.59 (s, 3H), 2.53 (s, 3H), 2.35-2.15 (m, 6H), 2.05-1.90 (m, 2H), 1.90-1.55 (m, 6H), 1.45-1.20 (m, 2H)

50 HCl salt

mp 181-184 °C

IR (KBr)ν_{max}: 3386, 2924, 1655, 1638, 1439, 1333, 1269, 1153, 1030 cm⁻¹.

MS (m/z): 686.18 (ES+, exact mass 685.23)

EXAMPLE 2

N-[1-[(2S)-1-[(2,4-DICHLORO-3-[(2,4-DIMETHYL-8-QUINOLINYL)OXY]METHYL]PHENYL]SULFONYL]PYRROLIDINYLCARBONYL]3-AZETIDINYL]EXO-8-METHYL-8-AZABICYCLO[3.2.1]OCTAN-3-AMINE

5 A. 1-Benzhydryl-3-azetidinol

[0070] A mixture of benzhydrylamine (25.0 g, 136 mmol), epichlorohydrine (12.6 g, 136 mmol) in MeOH (55 mL) was stirred for 3 days at room temperature. Then the mixture was stirred under reflux for 2 days. After cooling, the solvent was evaporated *in vacuo* and the resulting solid was washed with acetone (30 mL). Then the solid was suspended in Et₂O (500 mL) and washed with aqueous 6N NaOH (100 mL). The organic layer was dried over MgSO₄ and concentrated *in vacuo* to afford a product (13.6 g, 42%). This compound was used for the next reaction without further purification.

10 ¹H-NMR (CDCl₃) δ: 7.38-7.14 (m, 10H), 4.46-4.37 (m, 1H), 4.34 (s, 1H), 3.53-3.47 (m, 2H), 3.13 (brs, 1H), 2.92-2.86 (m, 2H)

B. 1-Benzhydryl-3-azetidinone

20 [0071] To a stirred solution of oxalyl chloride (21.6 g, 170 mmol) in CH₂Cl₂ (270 mL) was added DMSO (26.6 g, 340 mmol) at -78 °C. Then to the mixture was added dropwise a solution of 1-benzhydryl-3-azetidinol (13.6 g, 56.7 mmol) in CH₂Cl₂ (68 mL). After the mixture was stirred for 30 min, to the mixture was added triethylamine (51.6 g, 510 mmol) at -78 °C, and the resulting mixture was warmed to room temperature and stirred for 30 min before H₂O (50 mL) was added. The organic layer was separated, washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (SiO₂, 230-400 mesh, 300g, Hexane/AcOEt = 7/1 to 3/1) to give a product (10.0g, 75%) as a yellow crystal.

25 ¹H-NMR (CDCl₃) δ: 7.49-7.45 (m, 4H), 7.32-7.17 (m, 6H), 4.58 (s, 1H), 3.99 (s, 4H) C. N-(1-Benzhydryl-3-azetidinyl)-exo-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

30 [0072] To a stirred suspension of 1-benzhydryl-3-azetidinone (4.75g, 20.0 mmol) and *exo*-3-aminotropane (2.80g, 20.0 mmol) was added Ti(OiPr)₄ (8.9 mL, 30 mmol) and the mixture was stirred at room temperature for 4h. Then to the mixture was added MeOH (90.0 mL) to dissolve the resulting precipitate. The mixture was treated carefully with NaBH₄ (1.14 g, 30.0 mmol) and stirred for 16h at room temperature before adding saturated aqueous NaHCO₃ (10 mL). After the mixture was filtered through a pad of celite, the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (NH gel, 200-350 mesh, 120g, CH₂Cl₂/MeOH = 100/0 to 10/1) to give a product (3.45g, 48%) as a white solid.

D. *tert*-Butyl 1-benzhydryl-3-azetidinyl[*exo*-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]carbamate

35 [0073] To a stirred solution of *N*-(1-benzhydryl-3-azetidinyl)-*exo*-8-methyl-8-azabicyclo[3.2.1]octan-3-amine (3.45g, 9.54 mmol) in CH₂Cl₂ (19 mL) was added Boc₂O (2.08 g, 9.54 mmol) at room temperature and the mixture was stirred for 16h before adding saturated aqueous NaHCO₃ (10 mL). The organic layer was extracted with CH₂Cl₂ (100 mL), dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (NH gel, 200-350 mesh, 120 g, CH₂Cl₂/MeOH = 100/0 to 50/1) to give a product (4.13 g, 94%) as a yellow oil.

40 ¹H-NMR (CDCl₃) δ: 7.41-7.38 (m, 4H), 7.28-7.13 (m, 6H), 4.46 (s, 1H), 4.23-4.08 (m, 2H), 3.39-3.30 (m, 4H), 3.17 (brs, 2H), 2.32 (s, 3H), 2.08-1.98 (m, 4H), 1.66-1.58 (m, 2H), 1.50 (s, 9H), 1.38-1.32 (m, 2H)

E. *tert*-Butyl 3-azetidinyl[*exo*-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]carbamate

45 [0074] A mixture of *tert*-butyl 1-benzhydryl-3-azetidinyl[*exo*-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]carbamate (4.13g, 8.95 mmol) and Pd(OH)₂-C (20 wt% on carbon, 2.0g) in MeOH (41 mL) was stirred under hydrogen atmosphere (4 atm) at room temperature for 8h. After the mixture was filtered through a pad of celite (30% MeOH-CH₂Cl₂, 20 mL), the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (NH gel, 200-350 mesh, 120g, CH₂Cl₂/MeOH = 100/0 to 10/1) to give a product (3.0g, 100%) as a white solid.

50 [0075] F. N-[1-[(2S)-1-[(2,4-Dichloro-3-[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl]pyrrolidinyl]carbonyl]-3-azetidinyl]-*exo*-8-methyl-8-azabicyclo[3.2.1]octan-3-amine

[0075] The coupling product (*N*-Boc compound) was prepared by a procedure similar to that described in method

A. Then the product was dissolved in 0.3 mL of MeOH, to which was added 4 N HCl/dioxane (150 μ L, 600 μ mol). The mixture was agitated by swirling for 16 h at room temperature and concentrated to dryness. The deBoc compound was purified according to the procedure described in method A.

MS (m/z) : 686.59 (ES+, exact mass 685.23)

5

EXAMPLE 3

(2S)-N-[2-(3,8-DIAZABICYCLO[3.2.1]OCT-3-YL)-2-OXOETHYL]-1-[2,4-DICHLORO-3-[(2,4-DIMETHYL-8-QUINOLINYL)OXY]METHYL]PHENYL]SULFONYL]-2-PYRROLIDINECARBOXAMIDE

10

A. Diethyl meso-1-Benzyl-2,5-pyrrolidinedicarboxylate

[0076] A solution of Diethyl *meso*-2,5-dibromoadipate (50 g, 139 mmol) in benzene (150 mL) was heated to reflux. Then heating was discontinued and benzylamine (50 mL) was added under stirring in 1h. At the end of the addition, the mixture was refluxed for 20h. After cooling down, the hydrobromide salt was filtered off and washed with benzene, and the benzene solution was evaporated. The residue was distilled under reduced pressure (180-190 °C / 0.3 mmHg) to give a product (39.9 g, 94%) as a yellow oil.

¹H NMR (CDCl₃, 270 MHz) δ : 7.35-7.24 (m, 5H), 4.15-3.97 (m, 4H), 3.93 (s, 2H), 2.10-2.05 (m, 4H), 1.24 (t, J= 7.1Hz, 3H), 1.19 (t, J = 7.3Hz, 3H)

20

B. Diethyl meso-2,5-Pyrrolidinedicarboxylate

[0077] A mixture of diethyl *meso*-1-benzyl-2,5-pyrrolidinedicarboxylate (13.1 g, 43 mmol), Pd(OH)₂/C (20% wt, 6.5 g) in MeOH was hydrogenated at 4 atm for 5h. The mixture was filtered through celite. The filtrate was concentrated *in vacuo* to give a product (26.3 g, 94%) as a light yellow oil.

¹H NMR (CDCl₃, 270 MHz) δ : 4.24-4.15 (m, 4H), 3.99-3.94 (m, 1H), 3.85-3.77 (m, 2H), 2.24-1.86 (m, 4H), 1.28 (t, J = 7.1 Hz, 6H)

30

C. Ethyl (2S*, 5R*)-5-[(benzylamino)carbonyl]-2-Pyrrolidinedicarboxylate

[0078] A mixture of diethyl *meso*-2,5-pyrrolidinedicarboxylate (26.3 g, 122 mmol), benzylamine (13.1 g, 122 mmol) in xylene (80 mL) was refluxed for 18h. After cooling down, a white solid was separated. The filtrate was evaporated and the residue was distilled under reduced pressure to remove the byproducts. (byproducts 1st fraction, 55 °C/0.2 mmHg, 2nd fraction, 125 °C/0.2 mmHg) The crude residue (33 g) was used for the next step.

35

D. 3-Benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione

[0079] The crude ethyl (2S*, 5R*)-5-[(benzylamino)carbonyl]-2-Pyrrolidinedicarboxylate (33 g) was heated at 220 °C for 5h. Then the residue was distilled under reduced pressure (175 °C, 0.3 mHg) to give a yellow oil, which included a byproduct. Then a mixture of this yellow oil and the distillation residue was purified by column chromatography (SiO₂, 230-400 mesh, 30 g, Hexane/AcOEt = 2/1 to AcOEt only) to give the desired pure product (2.74g, 10%) as a yellow oil. ¹H NMR (CDCl₃, 270 MHz) δ : 7.31-7.23 (m, 5H), 4.80 (s, 2H), 4.15-4.11 (m, 2H), 2.26-2.15 (m, 2H), 1.95-1.88 (m, 2H)

40

E. 3-Benzyl-3,8-diazabicyclo[3.2.1]octane

45

[0080] To a stirred suspension of LiAlH₄ (1.37 g, 36.1 mmol) in dry Et₂O (23 mL) was added a solution of 3-benzyl-3,8-diazabicyclo[3.2.1]octane-2,4-dione (2.74 g, 11.9 mmol) in dry Et₂O (27.5 mL) dropwise at 0 °C. Then the mixture was refluxed for 46h. After cooling down, the mixture was quenched with H₂O (1.4 mL), 15% aq. NaOH (1.4 mL) and H₂O (4.1 mL) successively, filtered through celite. The filtrate was concentrated *in vacuo* to provide a product (2.3 g, 96%) as a yellow oil. This product was used for the next reaction without purification.

50

F. *tert*-Butyl 3-Benzyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

55

[0081] To a stirred solution of 3-benzyl-3,8-diazabicyclo[3.2.1]octane (2.30 g, 11.4 mmol) in CH₂Cl₂ (23 mL) was added Boc₂O (2.48 g, 11.4 mmol), and the mixture was stirred at room temperature overnight. Then the mixture was treated with saturated aqueous NaHCO₃ and the organic layers were extracted with CH₂Cl₂, dried over MgSO₄, and concentrated *in vacuo*. The residue was purified with column chromatography (SiO₂, 230-400 mesh, 69 g, Hexane only to AcOEt/Hexane = 1/20/, then 1/10) to give a product (2.2 g, 65%) as a colorless oil.

1H NMR (CDCl₃, 270 MHz) δ: 7.31-7.23 (m, 5H), 4.20-4.10 (m, 1H), 3.47 (s, 2H), 2.60 (dd, J = 11.0, 3.0 Hz, 2H), 2.35-2.20 (m, 1H), 1.92-1.77 (m, 4H), 1.46 (s, 9H)

5 G. *tert*-Butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0082] A mixture of *tert*-butyl 3-benzyl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, Pd(OH)₂-C (1.1 g) in MeOH (22 mL) was stirred under hydrogen atmosphere (4 atm) for 10 h at room temperature. The mixture was filtered through celite and the filtrate was concentrated *in vacuo* to give a product (1.45 g, 94%) as a white solid. This product was used for next step without purification.

10 H. *tert*-Butyl 3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetyl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0083] To a stirred solution of *N*-phthaloylglycine (725 mg, 3.53 mmol) and *tert*-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (500 mg, 2.36 mmol) in CH₂Cl₂ (20 mL) were added HOEt (481 mg, 3.53 mmol) and WSC (677 mg, 3.53 mmol) at room temperature and the mixture was stirred overnight. To the mixture was added H₂O (5 mL) and the organic layer was separated, washed with saturated aqueous NaHCO₃, brine, dried over MgSO₄, filtered and concentrated *in vacuo*. Flash chromatography (SiO₂, 230-400 mesh, 30 g, CH₂Cl₂-MeOH = 98 / 2 to 92 / 8) afforded the product as a white solid (713 mg, 81%).

15 ¹H NMR (CDCl₃, 270 MHz) δ: 7.90-7.85 (m, 2H), 7.75-7.70 (m, 2H), 4.55 (d, J=14.7Hz, 1H), 4.36 (d, J=14.7Hz, 1H), 20 4.35-4.14 (m, 2H), 3.52 (s, 2H), 3.00-2.92 (m, 1H), 2.06-1.65 (m, 3H), 1.49 (s, 9H)

20 I. *tert*-Butyl 3-(aminoacetyl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

[0084] To a stirred solution of *tert*-Butyl 3-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)acetyl]-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (70.0 mg, 0.187 mmol) in EtOH (1.9 mL) was added hydrazine monohydrate (19.0 mg, 0.375 mmol) at room temperature and the mixture was refluxed for 1h. After cooling, the precipitates formed were filtered off. The filtrate was evaporated *in vacuo* and the residue was purified by preparative TLC (SiO₂, 20x20 cm, 1 mm, CH₂Cl₂/MeOH / aqueous NH₃ = 92 / 6 / 2) to afford a product (21.4 mg, 42%) as a white solid.

25 ¹H NMR (CDCl₃, 270 MHz) δ: 4.30-4.20 (m, 3H), 3.50 (d, J=17.0Hz, 1H), 3.35 (d, J=17.0Hz, 1H), 3.36-3.30 (m, 2H), 3.00-2.87 (m, 2H), 2.00-1.90 (m, 2H), 1.72-1.58 (m, 2H), 1.48 (s, 9H)

30 J. (2*S*)-*N*-[2-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-1-[[2,4-dichloro-3-[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenylsulfonyl]-2-pyrrolidinecarboxamide

35 [0085] The titled compound was prepared by a procedure similar to that described in method A.

MS (m/z) : 660.37 (ES+, exact mass 659.17)

EXAMPLE 4

40 (2*S*)-1-[[2,4-DICHLORO-3-[(2,4-DIMETHYL-8-QUINOLINYLOXY)METHYL]PHENYL]SULFONYL]-*N*-(EXO-2-[(8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL)AMINO]-2-OXOETHYL)-2-PYRROLIDINECARBOXAMIDE, HCl SALT

45 A. Benzyl exo-3-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)aminol-2-oxoethylcarbamate

[0086] To a solution of *N*-Cbz-glycine (3.58 g, 17.1 mmol) and exo-3-aminotropone²⁾ (2.00 g, 14.3 mmol) in CH₂Cl₂ (71 mL) was added WSC (3.01 g, 15.7 mmol) at room temperature. After stirred at room temperature for 18 h, the reaction mixture was diluted with water (50 mL) and stirred at room temperature for 30 minute. The water phase was separated and extracted with CH₂Cl₂ (50 mL x2). The combined organic phase was washed with brine, dried over MgSO₄ and concentrated *in vacuo*. Flash chromatography of the residue (NH gel, 200-350 mesh, 150 g, CH₂Cl₂/MeOH =100/1 to 50/1) afforded a product (2.18 g, 46%) as a colorless oil.

50 ¹H NMR (CDCl₃, 270 MHz) δ: 7.41-7.29 (m, 5 H), 5.76 (brs, 1 H), 5.46 (brs, 1 H), 5.12 (s, 2 H), 4.20-4.01 (m, 1 H), 3.80 (d, J = 5.5 Hz, 2 H), 3.19-3.09 (m, 2 H), 2.26 (s, 3 H), 2.09-1.96 (m, 2 H), 1.86-1.40 (m, 6 H)

55 B. Exo-2-amino-*N*-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethanamide

[0087] A mixture of benzyl exo-3-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)aminol-2-oxoethylcarbamate (2.71 g, 8.17 mmol) and 10% Pd on carbon (8.13 mg) in MeOH (17 mL) was stirred under hydrogen atmosphere (1atm) at room

temperature for 18 h. Catalyst was removed by filtration and the filtrate was concentrated *in vacuo* to afford a product 1.48 g as a colorless oil. This crude product was used for the next reaction without further purification.

¹H NMR (CDCl₃, 270 MHz) δ: 4.30-4.10 (m, 1 H), 3.27 (s, 2 H), 3.30-3.10 (m, 2 H), 2.41 (s, 3 H), 2.18-2.10 (m, 2 H), 1.90-1.60 (m, 6 H)

C.(2S)-1-[[2,4-Dichloro-3-[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl]-N-[exo-2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-2-oxoethyl]-2-pyrrolidinecarboxamide, HCl salt

[0088] The title compound was prepared by a procedure similar to that described in method A-1

Free base

¹H-NMR (CDCl₃) δ: 8.12 (d, J=8.7 Hz, 1H), 7.62 (d, J=8.4 Hz, 1H), 7.57 (d, J=8.4Hz, 1H), 7.43 (t, J=7.9 Hz, 1H), 7.25-7.17 (m, 2H), 7.16 (s, 1H), 7.01 (t, J =5.5Hz, 1H), 5.65-5.54 (m ,2H), 4.43 (dd, J= 6.8, 4.6Hz, 1H), 4.10-3.92 (m, 2H), 3.83 (dd, J=5.2, 16.8Hz, 1H), 3.67-3.57 (m, 1H), 3.49 (dd, J=7.8, 16.1Hz, 1H), 3.05 (brs, 2H), 2.65 (brs, 6H), 2.17 (s, 3H), 2.20-2.15 (m, 2H), 2.02-1.90 (m, 4H), 1.75-1.57 (m, 4H), 1.25 (t, J=7.5Hz, 2H)

MS (m/z): 688.18 (ES+, exact mass 687.20)

HCl salt

mp 190-192 °C

EXAMPLE 5

(2S)-1-[[1-1-[[2,4-DICHLORO-3-[(2,4-DIMETHYL-8-QUINOLINYL)OXY]METHYL]PHENYL]SULFONYL]PYRROLIDINYLCARBONYL]4-PIPERIDINOPIPERIDINE, HCl SALT

[0089] The title compound was prepared by a procedure similar to that described in method A.

Free base

MS (m/z) : 659.19 (ES+, exact mass 658.21)

¹H-NMR (CDCl₃) δ: 8.16 (d, J=8.6 Hz, 1H), 7.61 (d, J=8.4 Hz, 1H), 7.46 (d, J=8.4Hz, 1H), 7.40 (t, J=8.2 Hz, 1H), 7.24 (d, J=8.6, 1.0Hz, 1H), 7.14 (s, 1H), 5.70-5.44 (m ,2H), 5.66 (s, 2H), 5.04-4.95 (m, 1H), 4.60-4.50 (m, 1H), 4.00-3.77 (m, 1H), 3.54-3.25 (m, 1H), 3.51-3.43 (m, 1H), 3.15-2.90 (m, 2H), 2.68 (s, 3H), 2.65(s, 3H), 2.60-2.40 (m, 5H), 2.30-1.30 (m, 14H)

HCl salt

mp 163-167 °C

EXAMPLE 6

(2S)-1-[[3-[(2,4-DIMETHYLQUINOLIN-8-YL)OXYMETHYL]-2,4-DICHLOROPHENYL]SULFONYL]-N-[3-[(3-AMINOCYCLOHEXYL)CARBONYL]AMINO]PROPYL]-2-PYRROLIDINECARBOXAMIDE, HCl SALT

A. 3-[(*tert*-Butoxycarbonyl)amino]cyclohexanecarboxylic acid

[0090] To a suspension of 3-aminocyclohexanecarboxylic acid (0.72 g, 5.0 mmol) in dioxane-H₂O (10 mL-5 mL) were added 1N aqueous NaOH (5.0 mL, 5.0 mmol) and di-*tert*-butyl dicarbonate (1.2g, 5.3 mmol) at 0°C. The mixture was stirred for 1 day at room temperature, and concentrated *in vacuo*. The residue was diluted with H₂O, acidified with 10% aqueous citric acid, and extracted with AcOEt. The extract was dried over MgSO₄, and filtered. Removal of solvent gave a product (0.97g, 76%) as a white solid.

¹H-NMR (CDCl₃) δ: 4.55-4.40 (1H, m), 3.55-3.35 (1H, m), 2.50-2.20 (2H, m), 2.03-1.80 (3H, m), 1.44 (9H, s), 1.40-0.95 (4H, m).

B. (2S)-1-[[3-[(2,4-Dimethylquinolin-8-yl)oxymethyl]-2,4-dichlorophenyl]sulfonyl]-N-[3-[(*tert*-butoxycarbonyl)amino]cyclohexylcarbonyl]amino]propyl]-2-pyrrolidinecarboxamide

[0091] To a stirred mixture of (2S)-1-[[3-[(2,4-dimethylquinolin-8-yl)oxymethyl]-2,4-dichlorophenyl]sulfonyl]-N-(3-aminopropyl)-2-pyrrolidinecarboxamide dihydrochloride¹) in CH₂Cl₂ (3 mL) was added triethylamine (33 μ l, 0.23 mmol) at room temperature. After stirring for 10 min, 3-[(*tert*-butoxycarbonyl)amino]cyclohexanecarboxylic acid (example6-A, 23 mg, 0.094 mmol), 1-hydroxybenzotriazole (13 mg, 0.094 mmol) and WSC (18 mg, 0.094 mmol) were added at room temperature. The mixture was stirred for 18h, washed with H₂O and saturated aqueous NaHCO₃. After removal of solvent, the residual oil was purified by column chromatography (SiO₂, 230-400 mesh, 1.5g, CH₂Cl₂/MeOH = 99/1 to 90/10) to provide a product (50 mg, 81%) as a colorless oil.

4 ¹H-NMR (CDCl₃) δ: 8.11 (1H, d, J=8.6 Hz), 7.64 (1H, d, J=8.2 Hz), 7.55 (1H, d, J=8.6 Hz), 7.44 (1H, t, J=8.2 Hz), 7.25
 5 (1H, d, J=8.2 Hz), 7.16 (1H, s), 6.95-6.85 (1H, m), 6.65-6.50 (1H, m), 5.66 (2H, s), 4.54-4.40 (2H, m), 3.65-3.05 (7H,
 10 m), 2.66 (3H, s), 2.65 (3H, s), 2.30-0.90 (15H, m), 1.43 (9H, s)

5 C. (2S)-1-[[3-[(2,4-Dimethylquinolin-8-yl)oxymethyl]-2,4-dichlorophenyl]sulfonyl]-N-[3-[(3-aminocyclohexyl)carbonyl]amino]propyl]-2-pyrrolidinecarboxamide, HCl salt


10 [0092] To a stirred solution of (2S)-1-[[3-[(2,4-dimethylquinolin-8-yl)oxymethyl]-2,4-dichlorophenyl]sulfonyl]-N-[3-[(3-aminocyclohexyl)carbonyl]amino]propyl]-2-pyrrolidinecarboxamide (50 mg, 0.063 mmol) in MeOH (3 mL) was added HCl-MeOH (1 mL) at room temperature, and the mixture was stirred for 18h. After removal of solvent, the residual solid was triturated with AcOEt, and collected to give a product (38 mg, 79%) as a white solid.

15 Free base

15 ¹H-NMR (CDCl₃) δ: 8.11 (1H, d, J=8.6Hz), 7.64 (1H, d, J=8.2Hz), 7.56 (1H, d, J=8.6Hz), 7.44 (1H, t, J=8.2Hz), 7.25 (1H, d, J=8.2Hz), 7.17 (1H, s), 7.00-6.90 (1H, m), 6.70-6.55 (1H, m), 5.64 (2H, s), 4.51 (1H, dd, J=3.2,8.2Hz), 3.65-3.05 (7H, m), 2.66 (3H, s), 2.65 (3H, s), 2.30-0.90 (15H, m)

MS (m/z): 690.22 (ES+, exact mass 689.22)

20 [0093] The chemical structures of the compounds prepared in the Examples 1 to 6 are summarized in the following table.




25 (wherein X¹ and X² are chloro; R¹ and R² are methyl; and R³ and R⁴ are hydrogen)

30 TABLE

Ex. #	R ⁵
1	4-(1-azabicyclo[2.2.2]octy-3-yl)-piperazin-1-yl
2	8-azabicyclo[3.2.1]octanyl aminoazetidin-1-yl
3	2-(3,8-diazabicyclo[3.2.1]oct-3-yl)-2-oxomethylamino
4	8-methyl-8-azabicyclo[3.2.1]oct-3-yl-amino oxomethylamino
5	piperidinopiperidinyl
6	[(3-aminocyclohexyl)carbonyl]amino]propylamino

50 **Claims**

55 1. A compound of the formula (I):



(I)

or the pharmaceutically acceptable salts thereof wherein

X¹ and **X²** are independently halo or C₁₋₄ alkyl;
R¹ and **R²** are independently hydrogen or C₁₋₄ alkyl;
R³ and **R⁴** are independently hydrogen or halo; and
R⁵ is

(a) -C₃₋₉ diazacycloalkyl optionally substituted with C₅₋₁₁ azabicycloalkyl;
(b) -C₃₋₉ azacycloalkyl-NH-(C₅₋₁₁ azabicycloalkyl optionally substituted with C₁₋₄ alkyl);
(c) -NH-C₁₋₃ alkyl-C(O)-C₅₋₁₁ diazabicycloalkyl;
(d) -NH-C₁₋₃ alkyl-C(O)-NH-C₅₋₁₁ azabicycloalkyl, the C₅₋₁₁ azabicycloalkyl being optionally substituted with C₁₋₄ alkyl;
(e) -C₃₋₉ azacycloalkyl optionally substituted with C₃₋₉ azacycloalkyl; or
(f) -NH-C₁₋₅ alkyl-NH-C(O)-C₄₋₉ cycloalkyl-NH₂.

2. A compound according to Claim 1, wherein

X¹ and **X²** are chloro;
R¹ and **R²** are independently hydrogen, methyl or ethyl;
R³ and **R⁴** are independently hydrogen or fluoro; and
R⁵ is

(a) -C₄₋₈ diazacycloalkyl optionally substituted with C₆₋₁₀ azabicycloalkyl;
(b) -C₃₋₆ azacycloalkyl-NH-(C₆₋₁₀ azabicycloalkyl optionally substituted with C₁₋₄ alkyl);
(c) -NH-C₁₋₃ alkyl-C(O)-C₆₋₁₀ diazabicycloalkyl;
(d) -NH-C₁₋₃ alkyl-C(O)-NH-C₆₋₁₀ azabicycloalkyl, the C₆₋₁₀ azabicycloalkyl being optionally substituted with C₁₋₄ alkyl;
(e) -C₄₋₈ azacycloalkyl optionally substituted with C₄₋₈ azacycloalkyl; or
(f) -NH-C₁₋₅ alkyl-NH-C(O)-C₅₋₈ cycloalkyl-NH₂.

3. A compound according to Claim 2, wherein R¹ and R² are methyl;

R³ and R⁴ are hydrogen; and
R⁵ is azabicyclo[2.2.2]octyl-piperazinyl, azabicyclo[3.2.1]octanylaminooazetidinyl, diazabicyclo[3.2.1]octyl-oxomethylamino, diazabicyclo[3.2.1]octyl-oxoethylamino, methylazabicyclo[3.2.1]octyl-aminooxomethylamino, methylazabicyclo[3.2.1]octylaminooxoethylamino, ethylazabicyclo[3.2.1]octyl-aminooxomethylamino, piperidinopiperidinyl, [(aminocyclohexyl)carbonyl]amino]propylamino or [(aminocyclohexyl)carbonyl]amino]butylamino.

4. A compound according to claim 3, wherein R⁵ is azabicyclo[2.2.2]octyl-piperazinyl, azabicyclo[3.2.1]octanylami-

noazetidinyl, diazabicyclo[3.2.1]octyl-oxomethylamino, methylazabicyclo[3.2.1]octylamino oxomethylamino, piperidinopiperidinyl or [(aminocyclohexyl)carbonyl]amino]propylamino.

- 5. A compound according to claim 1 selected from 8-[[3-[[2S]-2-[[4-[(3S)-1-Azabicyclo[2.2.2]oct-3-yl]-1-piperazinyl]carbonyl]pyrrolidinyl]sulfonyl]-2,6-dichlorobenzyl]oxy]-2,4-dimethylquinoline; and (2S)-N-[2-(3,8-Diazabicyclo[3.2.1]oct-3-yl)-2-oxoethyl]-1-[[2,4-dichloro-3-[(2,4-dimethyl-8-quinolinyloxy)methyl]phenyl]sulfonyl]-2-pyrrolidinecarboxamide, and a salt thereof.
- 10. A pharmaceutical composition which comprises a compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of the preceding claims and a pharmaceutically acceptable carrier.
- 15. A compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for use as a medicament.
- 20. The use of a compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for the manufacture of a medicament for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, pancreatitis, neovascularization, corneal haze, glaucoma, ocular pain or ocular hypertension.
- 25. The use of a compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for the manufacture of a medicament for the treatment of amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, multiple sclerosis, stroke, head trauma, post-surgical brain edema, brain edema (general), cytotoxic brain edema, brain edema associated with metabolic diseases, rheumatoid arthritis, osteoarthritis, migraine, neuropathic pain, pruritis, brain tumor, pseudotumor cerebri, glaucoma, hydrocephalus, spinal cord trauma, spinal cord edema, neurodegenerative diseases, respiratory diseases, diuresis, natriuresis, calcuresis, chronic obstructive pulmonary disease, post-traumatic brain injury, itching or sepsis.
- 30. The use of a compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for the manufacture of a medicament for the treatment of a disease condition mediated by bradykinin.
- 35. A compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for the treatment of a disease condition mediated by bradykinin.
- 40. A compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, pancreatitis, neovascularization, corneal haze, glaucoma, ocular pain or ocular hypertension.
- 45. A compound of the formula (I) or pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 5 for the treatment of inflammation, rheumatoid arthritis, cystitis, post-traumatic and post ischemic cerebral edema, liver cirrhosis, Alzheimer's disease, cardiovascular disease, pain, common cold, allergies, asthma, pancreatitis, burns, virus infection, head injury, multiple trauma, rhinitis, hepatorenal failure, diabetes, metastasis, pancreatitis, neovascularization, corneal haze, glaucoma, ocular pain or ocular hypertension.



DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)												
D, A	WO 98 03503 A (FOURNIER INDUSTRIE ET SANTÉ) 29 January 1998 (1998-01-29) * claims * ---	1,6,10	C07D453/02 A61K31/395 A61P43/00 C07D451/02 C07D487/08 C07D451/04 C07D401/14 C07D401/12 //(C07D487/08, 241:00,209:00)												
D, A	WO 98 24783 A (FOURNIER INDUSTRIE ET SANTÉ) 11 June 1998 (1998-06-11) * claims * -----	1,6,10													
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)												
			C07D A61K A61P												
<table border="1"> <tr> <td>Place of search</td> <td>Date of completion of the search</td> <td>Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>28 March 2002</td> <td>Van Bijlen, H</td> </tr> </table>				Place of search	Date of completion of the search	Examiner	THE HAGUE	28 March 2002	Van Bijlen, H						
Place of search	Date of completion of the search	Examiner													
THE HAGUE	28 March 2002	Van Bijlen, H													
<table border="1"> <tr> <td colspan="2">CATEGORY OF CITED DOCUMENTS</td> </tr> <tr> <td>X : particularly relevant if taken alone</td> <td>T : theory or principle underlying the invention</td> </tr> <tr> <td>Y : particularly relevant if combined with another document of the same category</td> <td>E : earlier patent document, but published on, or after the filing date</td> </tr> <tr> <td>A : technological background</td> <td>D : document cited in the application</td> </tr> <tr> <td>O : non-written disclosure</td> <td>L : document cited for other reasons</td> </tr> <tr> <td>P : intermediate document</td> <td>& : member of the same patent family, corresponding document</td> </tr> </table>				CATEGORY OF CITED DOCUMENTS		X : particularly relevant if taken alone	T : theory or principle underlying the invention	Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date	A : technological background	D : document cited in the application	O : non-written disclosure	L : document cited for other reasons	P : intermediate document	& : member of the same patent family, corresponding document
CATEGORY OF CITED DOCUMENTS															
X : particularly relevant if taken alone	T : theory or principle underlying the invention														
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date														
A : technological background	D : document cited in the application														
O : non-written disclosure	L : document cited for other reasons														
P : intermediate document	& : member of the same patent family, corresponding document														

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 01 31 0151

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-03-2002

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9803503	A	29-01-1998		FR 2751650 A1		30-01-1998
				AT 206419 T		15-10-2001
				AU 3853697 A		10-02-1998
				CA 2261743 A1		29-01-1998
				DE 69707141 D1		08-11-2001
				DK 925295 T3		28-01-2002
				EP 0925295 A1		30-06-1999
				WO 9803503 A1		29-01-1998
				JP 2000514818 T		07-11-2000
				PL 331347 A1		05-07-1999
				TR 9900096 T2		22-03-1999
				US 6071917 A		06-06-2000
-----	-----	-----	-----	-----	-----	-----
WO 9824783	A	11-06-1998		FR 2756562 A1		05-06-1998
				AU 5125798 A		29-06-1998
				EP 0944618 A1		29-09-1999
				WO 9824783 A1		11-06-1998
				JP 2001504854 T		10-04-2001
				PL 334088 A1		31-01-2000
				TR 9901242 T2		21-10-1999
				US 6063791 A		16-05-2000